Remi Barbier, CEO of Pain Therapeutics, Inc., presides over the closing bell.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. In December 2007, the Company announced that Remoxy(tm), an abuse-resistant, long-acting version of oxycodone, met the primary endpoint (p less than 0.01) of a pivotal Phase III study in over 400 patients with osteoarthritis; as a result, Pain Therapeutics plans to file an NDA for Remoxy in Q2 2008. Pain Therapeutics also has other drug candidates in clinical programs, including a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and Oxytrex(tm). In addition, the Company is working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of the Company's drug candidates. For more information, please visit www.paintrials.com.

Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.

For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at rob.tannenbaum@nasdaq.com.

© 2008, The NASDAQ OMX Group, Inc. Reprinted with permission.

Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search